Serum lipoprotein lipase mass: Clinical significance of its measurement

Clinica Chimica Acta

Volumn 378, Issue 1-2, 2007, Pages 7-12

  Kobayashi, Junji ^a   Nohara, Atsushi ^a   Kawashiri, Masa aki ^a   Inazu, Akihiro ^b   Koizumi, Junji ^c   Nakajima, Katsuyuki ^d   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Atherosclerosis; Carotid artery; Coronary artery; Triglycerides; Visceral fat

Indexed keywords

ADIPONECTIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN; ATORVASTATIN; BEZAFIBRATE; LIPOPROTEIN LIPASE; PITAVASTATIN; PRAVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; ENZYME BLOOD LEVEL; HUMAN; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

ANTILIPEMIC AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIPOPROTEIN LIPASE; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL;

EID: 33846920611     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.12.003     Document Type: Review

References (49)

1. Havel R.J., Kane J.P., and Kashyap M.L. Interchange of apolipoproteins between chylomicrons and high-density lipoproteins during alimentary lipemia in man. J Clin Invest 52 (1973) 32-38
2. Nilsson-Ehle P., Garfinkel A.S., and Schotz M.C. Lipolytic enzymes and plasma lipoprotein metabolism. Ann Rev Biochem 49 (1980) 667-693
3. Brunzell J.D., and Deeb S.S. Familial lipoprotein lipase deficiency, apo C-II deficiency and hepatic lipase deficiency. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic and molecular basis of inherited disease (2001), Mc Graw-Hill Inc., New York 2789-2816
4. Beisiegel U., Weber W., and Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low-density lipoprotein receptor-related protein. Proc Natl Acad Sci U S A 88 (1991) 8342-8346
5. Zheng C., Murdoch S.J., Brunzell J.D., and Sacks F.M. Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans. Arterioscler Thromb Vasc Biol 26 (2006) 891-896
6. Chappell D.A., Inoue I., Fry G.L., et al. Cellular catabolism of normal very low density lipoproteins via the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is induced by the C-terminal domain of lipoprotein lipase. J Biol Chem 269 (1994) 18001-18006
7. Nykjaer A., Nielsen M., Lookene A., et al. A carboxyl-terminal fragment of lipoprotein lipase binds to the low density lipoprotein receptor-related protein and inhibits lipase-mediated uptake of lipoprotein in cells. J Biol Chem 269 (1994) 31747-31755
8. Merkel M., Kako Y., Radner H., et al. Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake: direct evidence that lipoprotein lipase bridging occurs in vivo. Proc Natl Acad Sci U S A 95 (1998) 13841-13846
9. Cheng C.F., Oosta G.M., Bensadoun A., and Rosenberg R.D. Binding of lipoprotein lipase to endothelial cells in culture. J Biol Chem 256 (1981) 12893-12898
10. Scow R.O., Desnuelle P., and Verger R. Lipolysis and lipid movement in a membrane model. Action of lipoprotein lipase. J Biol Chem 254 (1979) 6456-6463
11. Saxena U., Klein M.G., and Goldberg I.J. Identification and characterization of the endothelial cell surface lipoprotein lipase receptor. J Biol Chem 266 (1991) 17516-17521
12. Vilella E., Joven J., Fernandez M., et al. Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins. J Lipid Res 34 (1993) 1555-1564
13. Tornvall P., Olivecrona G., Karpe F., Hamsten A., and Olivecrona T. Lipoprotein lipase mass and activity in plasma and their increase after heparin injection. Arterioscler Thromb Vasc Biol 15 (1995) 1086-1093
14. Watanabe H., Miyashita Y., Murano T., Hiroh Y., Itoh Y., and Shirai K. Preheparin serum lipoprotein lipase mass level: the effects of age, gender and type of hyperlipidemia. Atherosclerosis 145 (1999) 45-50
15. Tornvall P., Karpe F., Proudler A., et al. High-density lipoprotein: relations to metabolic parameters and severity of coronary artery disease. Metabolism 45 (1996) 1375-1382
16. Auwerx J.H., Babirak S.P., Fujimoto W.Y., Iverius P.H., and Brunzell J.D. Defective enzyme protein in lipoprotein lipase deficiency. Eur J Clin Invest 19 (1989) 433-437
17. Kern P.A., Martin R.A., Carty J., Goldberg I.J., and Ong J.M. Identification of lipoprotein lipase immunoreactive protein in pre- and postheparin plasma from normal subjects and patients with type I hyperlipoproteinemia. J Lipid Res 31 (1990) 17-26
18. Williams K.J., Fless G.M., Petrie K.A., Snyder M.L., Brocia R.W., and Swenson T.L. Mechanism by which lipoprotein lipase alters cellular metabolism of lipoprotein (a), low density lipoprotein, and nascent lipoproteins: Roles for low density lipoprotein receptors and heparan sulphate proteoglycans. J Biol Chem 267 (1992) 13284-13292
19. Kobayashi J., Saito K., Fukamachi I., et al. Pre-heparin plasma lipoprotein lipase mass: its correlation with intra-abdominal visceral fat accumulation. Horm Metab Res 33 (2001) 412-416
20. Hirano T., Nishioka F., and Murakami T. Measurement of the serum lipoprotein lipase concentration is useful for studying triglyceride metabolism: comparison with postheparin plasma. Metabolism 53 (2004) 526-531
21. Herranz L., Zapata A., Grande C., Megio A., and Pallardo L.F. Body fat distribution, insulin mediated suppression of non-esterified fatty acids and plasma triglycerides in obese subjects. Horm Metab Res 30 (1998) 141-145
22. Nakamura T., Tokunaga K., Shimomura I., et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107 (1994) 239-246
23. Walton C., Lees B., Crook D., Worthington M., Godsland I.F., and Stevenson J.C. Body fat distribution, rather then overall adiposity, influence serum lipids and lipoproteins in healthy men independently of age. Am J Med 99 (1995) 459-464
24. Rimm E.B., Stampfer M.J., Giovannucci E., et al. Body size and fat distribution as predictors of coronary heart disease among middle aged and older US men. Am J Epidemiol 141 (1995) 1117-1127
25. Bjorntop P. Abdominal obesity and the development of NIDDM. Diabetes Metab Rev 4 (1988) 615-619
26. Couillard C., Bergeron N., Prud'homme D., et al. Post-prandial triglyceride response in visceral obesity in men. Diabetes 47 (1998) 953-960
27. Kobayashi J., Tashiro J., Murano S., Morisaki N., and Saito Y. Lipoprotein lipase mass and activity in post-heparin plasma from subjects with intra-abdominal visceral fat accumulation. Clin Endocrinol 48 (1998) 515-520
28. Taira K., Hikita M., Kobayashi J., et al. Delayed post-prandial lipid metabolism in subjects with intra-abdominal visceral fat accumulation. Eur J Clin Invest 29 (1999) 301-308
29. Rip J., Nierman M.C., Wareham N.J., et al. Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 26 (2006) 637-642
30. Miyashita Y., Shirai K., Itoh Y., et al. Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract 56 (2002) 181-187
31. Kobayashi J., Maruyama T., Watanabe H., et al. Gender differences in the effect of type 2 diabetes on serum lipids, pre-heparin plasma lipoprotein lipase mass and other metabolic parameters in Japanese population. Diabetes Res Clin Pract 62 (2003) 39-45
32. Shirai K., Itoh Y., Sasaki H., et al. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 46 (1999) 35-41
33. Kobayashi J., Nagashima I., Hikita M., et al. Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol 47 (1999) 433-439
34. Kobayashi J., Tateishi S., Maruyama T., Kudoh A., and Murano S. Marked reduction in serum high-density lipoprotein cholesterol levels in a woman with acute inflammation due to diabetic gangrene. Clin Chim Acta 335 (2003) 33-38
35. Hanyu O., Miida T., Obayashi K., et al. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 174 (2004) 385-390
36. Kobayashi J., Kusunoki M., Murase Y., et al. Relationship of lipoprotein lipase and hepatic triacylglycerol lipase activity to serum adiponectin levels in Japanese hyperlipidemic men. Horm Metab Res 37 (2005) 505-509
37. De Vries R., Wolffenbuttel B.H., Sluiter W.J., van Tol A., and Dullaart R.P. Post-heparin plasma lipoprotein lipase, but not hepatic lipase activity, is related to plasma adiponectin in type 2 diabetic patients and healthy subjects. Clin Lab 51 (2005) 403-409
38. von Eynatten M., Schneider J.G., Humpert P.M., et al. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 27 (2004) 2925-2929
39. Saiki A, Oyama T, Endo K, et al. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract Sep 4 in press [Electronic publication ahead of print].
40. Hitsumoto T., Yoshinaga K., Aoyagi K., et al. Association between preheparin serim lipoprotein lipase mass and acute myocardial infarction in Japanese men. J Atheroscler Thromb 9 (2002) 163-169
41. Hitsumoto T., Ohsawa H., Uchi T., et al. Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis 153 (2000) 391-396
42. Taira K., Bujo H., Kobayashi J., Takahashi K., Miyazaki A., and Saito Y. Positive family history for coronary heart disease and 'midband lipoproteins' are potential risk factors of carotid atherosclerosis in familial hypercholesterolemia. Atherosclerosis 160 (2002) 391-397
43. Norioka M., Suzuki M., Ryomoto K., Ikebuchi M., and Harano Y. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects. J Atheroscler Thromb 7 (2000) 198-202
44. Totsuka M., Miyashita Y., Ito Y., Watanabe H., Murano T., and Shirai K. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Atherosclerosis 153 (2000) 175-179
45. de Man F.H., de Beer F., van der Laarse A., et al. The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding. Atherosclerosis 153 (2000) 363-371
46. Kobayashi J., Takahashi K., Tashiro J., et al. Effects of treatment with bezafibrate on lipoprotein lipase activity and mass in patients with hypertriglyceridemia. Arzneimittelforschung 44 (1994) 145-148
47. Saiki A., Murano T., Watanabe F., Oyama T., Miyashita Y., and Shirai K. Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb 12 (2005) 163-168
48. Endo K., Miyashita Y., Saiki A., et al. Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. J Atheroscler Thromb 11 (2004) 341-347
49. Kobayashi J., Maruyama T., Masuda M., and Shinomiya M. Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Clin Chim Acta 314 (2001) 261-264